ClinicalTrials.Veeva

Menu

Apatinib for Advanced Biliary Carcinoma

Fudan University logo

Fudan University

Status and phase

Unknown
Phase 2

Conditions

Biliary Tract Neoplasms

Treatments

Drug: Apatinib

Study type

Interventional

Funder types

Other

Identifiers

NCT03427242
FDZL-BTA

Details and patient eligibility

About

This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55 patients is planned for enrollment. The time for enrollment is from Nov 2017 to Nov 2020, the the follow-up will be ended after Nov 2021. Patients in the study would receive oral apatinib 500-750mg qd until progression of disease.

Enrollment

55 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients age between 18 and 70 years
  2. Histologically confirmed advanced biliary tract carcinoma (BTC) or metastatic BTC
  3. Prior lack of response or intolerance to at least one chemotherapeutic regimens (including gemcitabine).
  4. At least one measurable lesion as defined by RECIST 1.1
  5. An Eastern Cooperative Oncology Group performance status of 0 to 2
  6. Life expectancy ≥ 12 weeks
  7. For those who received other anti-tumor treatment, the damage should have been restored, with the time interval from last dose of nitroso or mitomycin≥6 weeks and interval from last dose of other cytotoxic drugs, radiation or surgery (the wound should be healed completely) ≥4 weeks.
  8. Acceptable hematologic, hepatic, and renal function within 7 days from screening: the blood ANC count≥1.5x109 /L; hemoglobin ≥ 9.0 g/dl,the blood platelet count≥80 x109 /L, total bilirubin < 1.5 x ULN, ALT and AST< 2.5 x ULN(< 5 x ULN for patients with live metastasis), serum creatinine≤1 x ULN,endogenous creatinine clearance rate >50ml/min
  9. Women of reproductive age need to take effective contraceptive measures

Exclusion criteria

  1. With other malignant tumor in 5 years,except for cured cervical carcinoma in situ or basal cell carcinoma.
  2. Uncontrolled blood pressure on medication (140/90 mmHg); patients with > Grade 1 coronary heart disease, cardiac arrhythmias or cardiac dysfunction
  3. Symptomatic brain or meningeal metastasis
  4. History of uncontrolled seizures, central nervous system dysfunction or mental disorder
  5. Uncontrolled pleural or peritoneal effusion
  6. Undergoing dialysis
  7. Severe or uncontrolled infection
  8. With multiple factors that affecting oral administration
  9. Abnormal coagulation function or those receiving thrombolytics or anticoagulants
  10. Patients with tendency of gastrointestinal hemorrhage, including active peptic ulcer with fecal occult blood ++, hematemesis or melena within 3 months
  11. Participation in other drug clinical trials within 4 weeks
  12. Weight below 40kg
  13. urine protein ≥2+

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

55 participants in 1 patient group

treatment arm
Experimental group
Description:
oral apatinib
Treatment:
Drug: Apatinib

Trial contacts and locations

1

Loading...

Central trial contact

Chenchen Wang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems